Victory Capital Management Inc. Sells 51,542 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Victory Capital Management Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 379,407 shares of the company's stock after selling 51,542 shares during the quarter. Victory Capital Management Inc. owned 0.40% of Vaxcyte worth $23,827,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Vaxcyte by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company's stock valued at $422,331,000 after purchasing an additional 47,872 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company's stock worth $234,442,000 after buying an additional 167,501 shares in the last quarter. Jennison Associates LLC raised its holdings in Vaxcyte by 20.6% in the third quarter. Jennison Associates LLC now owns 1,754,691 shares of the company's stock valued at $89,454,000 after acquiring an additional 300,189 shares in the last quarter. Westfield Capital Management Co. LP bought a new position in Vaxcyte during the 3rd quarter valued at $51,180,000. Finally, Northern Trust Corp grew its holdings in Vaxcyte by 4.1% during the 3rd quarter. Northern Trust Corp now owns 896,635 shares of the company's stock worth $45,710,000 after acquiring an additional 35,694 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 2,616 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $73.70, for a total value of $192,799.20. Following the sale, the chief executive officer now directly owns 148,670 shares in the company, valued at approximately $10,956,979. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Vaxcyte news, CEO Grant Pickering sold 2,616 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $73.70, for a total transaction of $192,799.20. Following the transaction, the chief executive officer now owns 148,670 shares of the company's stock, valued at approximately $10,956,979. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Elvia Cowan sold 11,678 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $74.08, for a total transaction of $865,106.24. Following the completion of the sale, the senior vice president now directly owns 12,480 shares of the company's stock, valued at $924,518.40. The disclosure for this sale can be found here. Insiders sold a total of 63,294 shares of company stock worth $4,254,105 in the last three months. 3.10% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a "buy" rating and issued a $95.00 target price on shares of Vaxcyte in a research note on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Thursday. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $78.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded down $1.22 during midday trading on Thursday, hitting $65.57. The company's stock had a trading volume of 919,643 shares, compared to its average volume of 813,824. The firm has a market cap of $7.11 billion, a P/E ratio of -15.80 and a beta of 0.94. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $82.04. The firm's fifty day moving average price is $66.14 and its 200-day moving average price is $62.45.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.28. As a group, research analysts predict that Vaxcyte, Inc. will post -4.18 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.